Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 2/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 10/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 6/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4251452 | 0.93 | RET (0.47) | RETGPR119EPHX2LMNAMAPT | |
| SCHEMBL13816772 | 0.84 | DDB1 (0.42) | RETGPR119LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4250231 | 0.82 | ESR2 (0.44) | GPR119LMNAMAPTSMN1; SMN2MAP4K4 | |
| SCHEMBL4854049 | 0.82 | GPR119 (0.46) | GPR119LMNAMAPTSMN1; SMN2MAP4K4 | |
| SCHEMBL4253695 | 0.81 | BACE1 (0.47) | RETLMNAMAPTMAP4K4 | |
| SCHEMBL4255027 | 0.81 | MAPT (0.40) | GPR119EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4253853 | 0.81 | ALDH1A1 (0.47) | GPR119EPHX2LMNAMAPTSMN1; SMN2 | |
| SCHEMBL4253786 | 0.80 | CHRNB2 (0.43) | RET | |
| SCHEMBL4251480 | 0.80 | ESRRB (0.39) | RETGPR119LMNAMAPTMAP4K4 | |
| SCHEMBL22638139 | 0.80 | FFAR4 (0.48) | RETGPR119LMNAMAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2009-06-18 | — | — | US | disclosed |
| EP-1892238-A1 | 1, 2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2008-02-27 | — | — | EP | disclosed |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | EISAI R&D MANAGEMENT CO., LTD. | 2006-12-14 | — | — | US | disclosed |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2006-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090156589-A1 | 1,2-DI(CYCLIC GROUP)SUBSTITUTED BENZENE DERIVATIVE | CCR10, H1-10, VCAM1 | RET 1757/4885GPR119 666/4885EPHX2 1333/4885 |
| US-20060281747-A1 | 1,2-di(cyclic) substituted benzene derivatives | CCR10, H1-10, CXCL10 | RET 1882/4885GPR119 988/4885EPHX2 1458/4885 |
| US-20060276465-A1 | 1,2-di(cyclic) substituted benzene compounds | HRH3, CCR10, HRH1 | RET 2375/4885GPR119 638/4885EPHX2 1005/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.